ʻO nā hōʻailona maʻi momona momona, Liver Biopsy, a me Cirrhosis i nā keiki

A HOLD Hoʻokuʻu ʻole 8 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

ʻO ka ʻikepili hou o ka honua e loiloi ana i ka alanine aminotransferase (ALT) i nā keiki i ʻike i nā ʻokoʻa i ka prevalence a me ke koʻikoʻi o ka maʻi momona momona ʻole (NAFLD). ʻO ke aʻo ʻana, Variation in Alanine Aminotransferase in Children with Non-Alcoholic Fatty Liver Disease, i paʻi ʻia i loko o ka puke pai peer-reviewed Children. Ua ʻohi ʻia ka ʻikepili mai ka pūʻulu nānā ʻana ʻo TARGET-NASH, kākoʻo ʻia e ke alakaʻi hōʻike honua maoli ʻo Target RWE.

Ua uluʻo NAFLD i hoʻokahi o nā maʻi maʻamau maʻamau, e pili ana i nā keiki e like me nā makahikiʻelua, a ke hoʻomau nei ka piʻiʻana o ka maʻi. ma waena o ke kāne a me ka lāhui / lāhui.

Hōʻike kēia haʻawina hou i ka hāʻawi ʻana i nā ʻano maʻi a me ka metabolic ma waena o nā keiki i kākau inoa ʻia i ka cohort data honua nui TARGET-NASH. Hoʻopili nā mea noiʻi i ka māhele ʻana o nā pae kiʻekiʻe ALT a me ka māhele ʻana o nā ʻano lapaʻau e ka mōʻaukala ʻelua o kahi biopsy a me ka pae kiʻekiʻe serum ALT (≤70, >70 a ≤250, a me >250 U/L) e ʻike i nā comorbidities a me nā ʻano lapaʻau. i kēia ulu ʻana, akā ʻaʻole i hoʻonaʻauao ʻia.

He 660 mau keiki me ka makahiki waena o 13 makahiki. Loaʻa nā ʻike nui:

• He 187 mau keiki i loaʻa i ka biopsy, ua ʻoi aku ka nui o ka Hispanic a i ʻole Latino (67% vs. 57%) a me ka cirrhosis (10% vs. 1%).

• 'O ka ma'i nui o ka cirrhosis a i 'ole kekahi pae fibrosis o ke akepa'a ka mea ma'amau i waena o nā keiki me ka ALT ki'eki'e > 70 U/L.

• He 2 manawa ka nui o ka ma'i diabetes type 2.2 ma waena o nā keiki me ka ALT >250 U/L i ho'ohālikelike 'ia me nā keiki me ka ALT ki'eki'e ma waena o 71 a me 250 a me nā keiki me ka ALT ki'eki'e ≤ 70 U/L.

"He helu kamahaʻo nui o nā maʻi pediatric me ka ALT kiʻekiʻe ma mua o 250 i loko o kēia cohort honua maoli," wahi a Eduardo Castillo-Leon, MD, Department of Pediatrics, School of Medicine, Emory University. "ʻO nā haʻawina mua e nānā ana i ka NAFLD pediatric i hana nui ʻia i nā hoʻokolohua hoʻokele me nā koina hoʻokomo / hoʻokaʻawale kikoʻī a me ka hiki ʻole ke nānā i ka piʻi ʻana o ka manawa i ka heluna honua maoli. ʻO nā pae hoʻokomo ākea no kēia haʻawina i ʻae ʻia i ka nānā ʻana o kēlā mau maʻi me nā waiwai maʻamau a haʻahaʻa haʻahaʻa o ALT, kahi heluna kanaka i nānā ʻole ʻia.

"ʻO nā kiʻekiʻe kiʻekiʻe o ka ALT i pili me ka piʻi nui ʻana o nā comorbidities a me nā pae kiʻekiʻe o NAFLD, ʻoi aku hoʻi ma waena o nā keiki Hispanic," wahi a Miriam Vos, MD, MSPH, Keʻena o Pediatrics, Kula o ka Lapaʻau, Ke Kulanui ʻo Emory, a me ke kauka ma ka Healthcare o nā keiki. Atlanta. "Ke kākoʻo nei kēia mau ʻike i ka nui o ka pono no ka therapeutics a me ka loiloi ʻana i ka maʻi maʻi i nā keiki me nā pae kiʻekiʻe ALT."

Hoʻopili ʻia nā loiloi i nā keiki i kākau inoa ʻia ma waena o ʻAukake 1, 2016, a me ʻOkakopa 12th, 2020, me hoʻokahi ana ALT ma hope o ke kau inoa ʻana.

ʻO TARGET-NASH he pūʻulu nānā lōʻihi maoli o ka poʻe mākua a me nā keiki me ka NAFLD a / a i ʻole NASH e loaʻa ana ka mālama maʻamau mai nā kikowaena kula a me nā kaiāulu ma US a me ʻEulopa, e kākau inoa ana ma luna o 7,000 mau mea komo a hiki i kēia lā.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...